Human Anti-MS4A1 Recombinant Antibody (clone huCD20-7) (CAT#: HPAB-1587-FY)

Figure 1 Depicts binding of muCD20-7, chCD20-7 and huCD20-7 but not hulgGl isotype control antibody to BJAB cells as assayed by flow cytometry.

The binding curves were used to determine the EC50 of antibody binding, which corresponds to the apparent Kd of each antibody.

Figure 2 Depicts binding of huCD20-7 to a membrane preparation from WSU-lymphoma cells by ELISA.

Figure 3 Depicts the results of an Annexin-V assay on Ramos lymphoma cells incubated with huCD20-7, B1, rituximab, GA101-F, and 2F2.

At concentrations ranging from 3 x 10-8M to 1.7 x 10-13M.

Figure 4 Depicts the results of CDC assays on Daudi lymphoma cells incubated with huCD20-7, rituximab, GA101-F or a huIgGi isotype control antibody in the presence of 5% human serum having complement.

Figure 5 Depicts the results of an ADCC assay using Ramos lymphoma cells incubated with huCD20-7, rituximab, 2F2 or a hu1gG1 isotype control antibody in the presence of purified human NK cells as effector cells.

Figure 6 Depicts binding of huCD20-7 in comparison with huCD20-7-SMCC-DM1 and -SPP-DM1 conjugates to a membrane preparation from WSU-DLCL-2 lymphoma cells by ELISA.

Figure 7 Depicts the results of ADCC assays on Ramos lymphoma cells incubated with huCD20-7, huCD20-7-SMCC-DM1, rituximab, 2F2 or a hulgGl isotype control antibody in the presence of purified human NK cells as effector cells.

Figure 8 Depicts the results of CDC assays on WSU-DLCL-2 lymphoma cells incubated with huCD20-7, huCD20-7-SMCC-DMI, huCD20-7-sulfo-mal-DM4, rituximab or a hulgGl isotype control antibody in the presence of 5% human serum having complement.

Figure 9 Depicts the results of a WST-8 cytotoxicity assay on Ramos cells incubated with huCD20-7, huCD20-7-SMCC-DM1, rituximab or hulgGl-SMCC-DM1 control conjugate at concentrations ranging from 3 x 10-8M to 1 x 10-11M for 5 days.

Figure 10 Depicts the results of a WST-8 cytotoxicity assay on Granta-519 cells incubated with huCD20-7, huCD20-7-SMCC-DMI, rituximab or a non-binding hulgGl-SMCC-DM1 control conjugate at concentrations ranging from 3 x 10-8M to 1 x 10-"M for 5 days.

Figure 11 Depicts results of experiments using an established xenograft model SU-DHL-4 diffuse large B-cell lymphoma cells implanted subcutaneously into SCID mice.

Mice were treated three times weekly on days 14, 21 and 28 (arrows) post cell inoculation with either 10 or 1 mg/kg of huCD20-7 or rituximab.

Figure 12 Depicts the results of an exemplary xenograft study using DOHH-2 follicular lymphoma cells implanted subcutaneous into SCID mice.

Mice were treated once on day 3 post cell inoculation with either 10 mg/kg of huCD20-7, 10 mg/kg of huCD20-7-SMCC-DM 1 or 5 mg/kg of huCD20-7-SPP-DM1.